Arbutus Biopharma (ABUS) Non-Current Deffered Revenue (2017 - 2025)
Historic Non-Current Deffered Revenue for Arbutus Biopharma (ABUS) over the last 12 years, with Q1 2025 value amounting to $2.9 million.
- Arbutus Biopharma's Non-Current Deffered Revenue changed N/A to $2.9 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.9 million, marking a year-over-year change of. This contributed to the annual value of $2.9 million for FY2024, which is N/A changed from last year.
- Per Arbutus Biopharma's latest filing, its Non-Current Deffered Revenue stood at $2.9 million for Q1 2025.
- Arbutus Biopharma's Non-Current Deffered Revenue's 5-year high stood at $15.6 million during Q1 2022, with a 5-year trough of $2.9 million in Q4 2024.
- Moreover, its 4-year median value for Non-Current Deffered Revenue was $6.0 million (2022), whereas its average is $7.4 million.
- Examining YoY changes over the last 5 years, Arbutus Biopharma's Non-Current Deffered Revenue showed a top increase of 7885.15% in 2023 and a maximum decrease of 7885.15% in 2023.
- Arbutus Biopharma's Non-Current Deffered Revenue (Quarter) stood at $6.0 million in 2022, then crashed by 45.06% to $3.3 million in 2023, then decreased by 13.14% to $2.9 million in 2024, then changed by 0.0% to $2.9 million in 2025.
- Its Non-Current Deffered Revenue was $2.9 million in Q1 2025, compared to $2.9 million in Q4 2024 and $3.3 million in Q1 2023.